[abstract] MANAGEMENT OF THE INTESTINAL ISCHAEMIA, NECROTIZING ENTEROCOLITIS AND ANOXIC ENCEPHALOPHATIES OF NEONATES WITH HYPERBARIC OXYGEN THERAPY.

Rubicon Research Repository/Manakin Repository

[abstract] MANAGEMENT OF THE INTESTINAL ISCHAEMIA, NECROTIZING ENTEROCOLITIS AND ANOXIC ENCEPHALOPHATIES OF NEONATES WITH HYPERBARIC OXYGEN THERAPY.

Show full item record


Title: [abstract] MANAGEMENT OF THE INTESTINAL ISCHAEMIA, NECROTIZING ENTEROCOLITIS AND ANOXIC ENCEPHALOPHATIES OF NEONATES WITH HYPERBARIC OXYGEN THERAPY.
Author: Sanchez, EC; Montes, G; Oroz, G; Garcia, L
Abstract: BACKGROUND: Hyperbaric treatment on neonates started in the 60's but almost completely stopped in the 70's. We believe neonates can be effectively managed in a monoplace chamber. OBJECTIVE: To determine the value of HBO2 in the management of intestical ischemia, necrotizing enterocolitis and anoxic encephalopathy of neonates, and to determine the incidence of ocular, pulmonary and CNS oxygen toxicity. DESIGN: Prospective pilot study. METHODS: Neonates with intestinal ischemia, necrotizing enterocolitis or anoxic encephalopathy older than 34 weeks of gestation and above 1,200 g of weight, were evaluated and treated in a Sechrist monoplace chamber (3200) with a neonatologist as an inside attendant. Treatment consisted of HBO2 2.0 atm abs/45 min/ BID (one air break of 5 minutes included). Preventative myringotomies were done before the first treatment. EEG, evoked potential, ophthalmic evaluation ultrasound and X-rays were obtained before first treatment and after HBO2. A follow up was done at 3, 6, and 12 weeks. RESULTS: All patients (n=7) were ventilator dependant and required ambu ventilation by a neonatologist during the treatment. All of the patients treated within 6 hours of delivery resolved with only one treatment. Those treated after 24 h required more than one treatment, two of which developed pulmonary oxygen toxicity, but responded well to inhaled steroids and surfactant (Survanta). Sepsis and DIC resolved after the first treatment, as did cerebral edema. No opthalmic side effects were detected after HBO2, and at 3 and 6 month follow-up. All patients were monitored with tcPo2 that allowed us to eveluate each patients ventilatory status. CONCLUSIONS: Preliminary results suggest that HBO2 is a safe and effective treatment in noenates. There is a need for a prospective, randomized, controlled and double-blinded study to determine precisely the place of HBO2 in the management of acute ischemic/hypoxic conditions neonates.
Description: Undersea and Hyperbaric Medical Society, Inc. (http://www.uhms.org )
URI: http://archive.rubicon-foundation.org/791
Date: 1999

Files in this item

Files Size Format View
abstract.txt 259bytes Text file View/Open

This item appears in the following Collection(s)

  • UHMS Meeting Abstracts
    This is a collection of the published abstracts from the Undersea and Hyperbaric Medical Society (UHMS) annual meetings.

Show full item record

Browse

My Account